Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP: ESALY )

42.58 +0.78 (+1.87%)
Streaming Delayed Price Updated: 3:50 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,790
Open 42.17
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 41.80
Today's Range 42.17 - 42.58
52wk Range 36.88 - 104.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
Eisai finished submitting its application for lecanemab, another anti-amyloid drug. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-24.88%
-24.88%
1 Month
+3.69%
+3.69%
3 Month
-10.04%
-10.04%
6 Month
-26.59%
-26.59%
1 Year
-59.07%
-59.07%

More News

Read More
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Via Benzinga
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
Via Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
Via Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
Via Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
Via Benzinga
News-Filled Day
Via Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
Hopes For A Peace Accord
Via Talk Markets
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
Via Benzinga
The Ruble Is Rubble
Via Talk Markets
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
Via Benzinga
Dampening Exuberance
Via Talk Markets
Weakened Tech Stocks
Via Talk Markets
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Via Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
Via Benzinga
Christmas is Coming
Via Talk Markets
A Bit Of Good News
Via Talk Markets
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
Via Benzinga
Uncertain Times
Via Talk Markets
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
Via Benzinga
Why Are Biogen Shares Gaining Today?
Via Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
Via Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.